SAN DIEGO — NexMed USA on Thursday received clearance from the Food and Drug Administration to market the company's first over-the-counter antifungal drug, Tolnaftate-D.
NexMed USA's Tolnaftate-D incorporates NexACT, a proprietary drug delivery technology that transiently loosens the tight junction between the cells of the sealed skin to allow more permeation.
